Time Pharmaceuticals Moving Ahead With Book-Building IPO

6th July 2026, Kathmandu

Pharmaceutical manufacturer Time Pharmaceuticals Limited has formally advanced the regulatory process of issuing an initial public offering through the book-building method.

Time Pharmaceuticals Moving Ahead 

The manufacturing enterprise has proposed a floor price of NPR 600 per share for qualified institutional investors. To support the upcoming equity float, the corporate management recently conducted a structured roadshow interact program inside the capital city.

The strategic investor assembly took place at the Hotel Yak and Yeti complex in Kathmandu, recording active participation from representatives of more than 145 qualified institutional investors. During the interactive session, corporate directors presented the company’s current financial position, past dividend capacities, upcoming production plant expansion models, long-term commercial goals, and technical details surrounding the book-building allocation mechanism.

IPO SIZE AND SHARE ALLOCATION STRATEGIES

The pharmaceutical producer plans to issue 1,086,500 ordinary units of shares valued at NPR 108.65 million at par value. This specific volume represents approximately 20.5 percent of the company’s total established issued capital, which sits at NPR 530 million.

The institutional share distribution framework operates according to structured allocations managed under the book-building guidelines. The total issue will be split into two primary investor categories:

• Qualified Institutional Bidders: 40 percent of the total issue volume, which equals exactly 434,600 ordinary shares, has been legally reserved for qualified institutional investors.
• General Public Offering: The remaining 60 percent portion of the total stock pool will be offered to general public retail investors, non-resident Nepali workers, and internal staff members during the secondary phase.

PRICING DETAILS AND BID SCHEDULES

The company has determined an average corporate valuation price of NPR 666.78 per share based on various accounting methodologies, including discounted cash flows, net worth assessments, and relative price-to-earnings multiples. For the corporate entities participating in the book-building pricing discovery window, the baseline floor price has been set at NPR 600 per share.

The corporate management distributed Indication of Interest forms during the assembly to log early demand curves. Institutional asset managers can collect and register these specific filing papers across two designated offices:

Advertisement

• Nabil Investment Banking Limited, Central Counter, Kathmandu.
• Time Pharmaceuticals Limited, Corporate Office, Lalitpur.

According to Company Secretary and Advocate Sudip Ghimire, the public offering process follows the rigid structural rules of the Book Building Directive 2077. A sealed bidding operation agreement was previously signed on Chaitra 24 between the Nepal Stock Exchange and Time Pharmaceuticals Limited to launch the system. A coordination committee comprising representatives from the stock exchange, the issuer, and the issue manager has been actively monitoring the timeline.

The approved regulatory schedule outlines specific dates for pricing operations:

• Institutional Sealed Bid Submission Window: Running from Ashar 22 through Ashar 26.
• Official Opening of Sealed Bids: Scheduled to occur on Ashar 29 to calculate the final cutoff pricing boundaries.

COMPANY GROWTH AND CLINICAL SECTOR TRANSFORMATION

Chairman Dr. G. Narayan Bahadur Kshetri stated that the manufacturing concern initiated its commercial production timeline nearly 29 years ago. The business started with a small asset base of NPR 10 million in capital, a team of 25 pioneer employees, and a portfolio consisting of only 8 pharmaceutical products.

Through systematic factory upgrades and expanded therapeutic offerings, the enterprise has grown significantly. The company now manages an authorized capital structure of NPR 600 million, employs more than 350 medical professionals and production staff, and manufactures over 200 high-quality pharmaceutical products covering multiple healthcare departments.

The chairman also noted that Time Pharmaceuticals Limited has initiated Nepal’s first formal clinical trial within the domestic pharmaceutical sector. The scientific study report is undergoing final analysis and will be made public soon to support local medicine development.

PUBLIC ACCESS TO IPO ACCREDITATION DOCUMENTS

To guarantee absolute financial transparency for institutional asset appraisers, the corporation has uploaded its complete statutory financial records online. The draft prospectus, internal financial statements, independent valuation reports, and credit rating certifications are fully accessible through the official web pages of both Time Pharmaceuticals Limited and Nabil Investment Banking Limited.

The upcoming stock issuance will stand as a notable public offering within Nepal’s domestic pharmaceutical industry to deploy the book-building method. This framework allows real institutional demand to determine the final balanced market price before the retail investment phase opens to the general public.

For More: Time Pharmaceuticals Moving Ahead